IBD in Black Adults: Signs, Diagnosis, and Care

Inflammatory bowel disease (IBD) is a group of chronic conditions where the immune system attacks the digestive tract. The two main forms are Crohn's disease, which can inflame any part of the gut from mouth to anus, and ulcerative colitis, which inflames the colon and rectum. Both cause flares of bloody diarrhea, cramping abdominal pain, urgency, and weight loss. Neither is caused by something you ate or did. For decades clinicians were taught that Black and Hispanic people did not get IBD, and that assumption still costs Black patients time, specialty care, and intestines.

An estimated 2.4 million American adults live with IBD, roughly 1 in 100. White Americans still carry the highest prevalence at 812 per 100,000, compared with 504 per 100,000 in Black Americans, but those numbers describe the past, not the trend. A population-based study in Olmsted County, Minnesota tracked incidence from 1970 to 2010 and found IBD rose 134% in non-white residents over those four decades, against a 39% rise in white residents. Non-white incidence climbed from 35% of the white rate in the early years to 60% by 2000 to 2010. The disease is converging, and the clinical reflex that IBD does not happen in Black patients is now actively dangerous.

The most common symptoms of Crohn's disease are diarrhea, cramping and pain in the abdomen, and weight loss, often with fatigue, low-grade fever, and anemia from blood loss. Ulcerative colitis centers on the colon: diarrhea, rectal bleeding, passing blood with stool, lower abdominal cramping, and tenesmus, the constant urge to move your bowels even when nothing comes. In severe ulcerative colitis a person can have more than six bloody bowel movements a day. Both diseases run in cycles of flare and remission, so symptoms that fade on their own do not mean the disease is gone.

Black patients more often present with the aggressive end of the spectrum. In Crohn's disease, Black patients show more perianal disease and a higher proportion of penetrating disease, the type that burrows fistulas and abscesses through the bowel wall. A 2025 nationwide cohort found Black patients with Crohn's had higher rates of anal abscess (2.88% vs 1.25%, 41% higher adjusted odds) and rectal bleeding (2.85% vs 1.79%, 42% higher odds) than white patients. In ulcerative colitis, Black patients had higher rates of rectal bleeding (9.0% vs 5.7%). More severe presentations make early, accurate diagnosis matter more, not less.

Irritable bowel syndrome (IBS) and IBD share an acronym and some symptoms, and they are routinely confused, which delays IBD care. IBS is a disorder of how the gut and brain communicate. It causes pain, bloating, and altered bowel habits, but it does not inflame or damage the bowel and it does not cause bleeding, fever, or weight loss. IBD is structural, immune-driven inflammation that shows up on a colonoscopy and in blood and stool tests, and left untreated it scars and narrows the gut. If you have been told you have IBS but you are passing blood, losing weight, waking at night to use the bathroom, or running fevers, those are not IBS symptoms. Ask to be evaluated for IBD.

There is no single blood test for IBD. Diagnosis combines your history with labs and direct imaging of the bowel. Blood work checks for anemia and inflammation markers such as C-reactive protein. A stool test for fecal calprotectin flags gut inflammation and helps separate IBD from IBS. The definitive step is a colonoscopy, where a gastroenterologist looks at the lining of the colon and takes biopsies to confirm inflammation and tell Crohn's from ulcerative colitis. Crohn's higher in the small bowel may also need cross-sectional imaging or a capsule study. Because the colonoscopy is the anchor, getting in front of a gastroenterologist is the bottleneck, and that is exactly where Black patients fall behind.

The disparities in IBD are about access and assumption, not biology. Black patients with IBD are less likely to receive care from gastroenterologists and IBD specialists than comparable white patients, and they have a greater frequency of emergency room visits. Patients describe being told their race is not appropriate for their disease, that IBD is a disease of white or Jewish people. When the first stop is the ER instead of a GI clinic, diagnosis tends to come after a complication, a bowel obstruction, an abscess, a hospitalization, rather than before.

The treatment gap follows the access gap. Modern IBD is controlled with biologic and small-molecule drugs: anti-TNF agents like infliximab and adalimumab, plus ustekinumab, vedolizumab, and tofacitinib. These drugs change the course of the disease and prevent surgery. Retrospective studies show Black patients are less likely to receive biologic therapies than white patients. That is the core injustice of IBD care: the patients with more penetrating, abscess-prone disease are getting fewer of the drugs that prevent exactly those complications.

Get to a gastroenterologist, and do not let the first dismissal end it. Bring a written timeline of your symptoms, note any blood, weight loss, night-time bathroom trips, and fevers, and ask specifically: could this be Crohn's or ulcerative colitis, and do I need a colonoscopy and a fecal calprotectin test? If you have a family history of IBD, say so. A clinician who takes your community and your symptoms seriously changes the timeline, so if you want a doctor attuned to how IBD shows up in Black patients, find a Black gastroenterologist or a GI clinic that serves Black communities. Because colonoscopy is also how colon cancer is caught, this is a good moment to confirm you are current on colorectal cancer screening, which now starts at 45.